INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 188 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $377,000 | -78.3% | 10,119 | -76.3% | 0.05% | -79.8% |
| Q2 2021 | $1,739,000 | +311.1% | 42,611 | +242.0% | 0.26% | +242.7% |
| Q1 2021 | $423,000 | -50.0% | 12,459 | -53.2% | 0.08% | -56.9% |
| Q4 2020 | $846,000 | +18.8% | 26,606 | -4.1% | 0.17% | -4.4% |
| Q3 2020 | $712,000 | +33.8% | 27,737 | +33.9% | 0.18% | +2.2% |
| Q2 2020 | $532,000 | +9.7% | 20,714 | -34.4% | 0.18% | -12.3% |
| Q1 2020 | $485,000 | -48.6% | 31,554 | -56.6% | 0.20% | -8.6% |
| Q2 2019 | $944,000 | +30.9% | 72,758 | +14.9% | 0.22% | +14.4% |
| Q4 2018 | $721,000 | +79.4% | 63,304 | +231.6% | 0.19% | +115.6% |
| Q1 2018 | $402,000 | +64.8% | 19,088 | +13.4% | 0.09% | +66.7% |
| Q4 2017 | $244,000 | -16.2% | 16,826 | -8.7% | 0.05% | -16.9% |
| Q3 2017 | $291,000 | – | 18,429 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |